An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects
Sponsor: Janssen R&D Ireland
A PHASE3 clinical study on Hepatitis C, this trial is completed. The trial is conducted by Janssen R&D Ireland and has accumulated 7 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen R&D Ireland
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam-Zuidoost, Netherlands , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Atlanta, United States , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Bratislava, Slovakia , Bruges, Belgium , Brussels, Belgium and 50 more locations